Hyponatremia in cirrhosis: Pathophysiology and management

World Journal of Gastroenterology

Volumn 21, Issue 11, 2015, Pages 3197-3205

  John, Savio ^a   Thuluvath, Paul J ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Dilutional hyponatremia; Hypervolemic hyponatremia; Hyponatremia in cirrhosis; Vaptans; Vasopressin receptor antagonists

Indexed keywords

ALBUMIN; ARGIPRESSIN; CONIVAPTAN; KAPPA OPIATE RECEPTOR AGONIST; LIXIVAPTAN; SATAVAPTAN; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; LOOP DIURETIC AGENT;

ADRENERGIC SYSTEM; DRUG THERAPY; FLUID BALANCE; FLUID RESUSCITATION; HUMAN; HYPOKALEMIA; HYPONATREMIA; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PATIENT CARE; PLASMA TRANSFUSION; PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM BLOOD LEVEL; VASODILATATION; WATER DEPRIVATION; ADVERSE EFFECTS; ANIMAL; ASCITES; COMPLICATION; DRUG EFFECTS; ELECTROLYTE BALANCE; FLUID THERAPY; HYPERTENSION, PORTAL; PATIENT SELECTION; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; ASCITES; FLUID THERAPY; HUMANS; HYPERTENSION, PORTAL; HYPONATREMIA; LIVER CIRRHOSIS; PATIENT SELECTION; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 84925679701     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i11.3197     Document Type: Review

References (70)

1. Baran D, Hutchinson TA. The outcome of hyponatremia in a general hospital population. Clin Nephrol 1984;22:72-76 [PMID: 6478674]
2. Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, Liard JF, Martin PY, Schrier RW. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851-864 [PMID: 9731583 DOI: 10.1002/hep. 510280337]
3. Angeli P, Wong F, Watson H, Ginès P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44:1535-1542 [PMID: 17133458 DOI: 10.1002/hep. 21412]
4. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994;20:1356-1358 [PMID: 7927272 DOI: 10.1002/hep. 1840200537]
5. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-1363 [PMID: 7927273 DOI: 10.1002/hep. 1840200538]
6. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157 [PMID: 2971015 DOI: 10.1002/hep. 1840080532]
7. Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997;17:175-189 [PMID: 9308123 DOI: 10.1055/s-2007-1007196]
8. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776-778 [PMID: 1706450 DOI: 10.1016/0140-6736 (91) 91384-7]
9. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-S131 [PMID: 16447289 DOI: 10.1002/hep. 20993]
10. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80 [PMID: 9148026]
11. Such J, Francés R, Muñoz C, Zapater P, Casellas JA, Cifuentes A, Rodríguez-Valera F, Pascual S, Sola-Vera J, Carnicer F, Uceda F, Palazón JM, Pérez-Mateo M. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002;36:135-141 [PMID: 12085357 DOI: 10.1053/jhep. 2002.33715]
12. Francés R, Benlloch S, Zapater P, González JM, Lozano B, Muñoz C, Pascual S, Casellas JA, Uceda F, Palazón JM, Carnicer F, Pérez-Mateo M, Such J. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004;39:484-491 [PMID: 14768002 DOI: 10.1002/hep. 20055]
13. Guarner C, Soriano G, Such J, Teixidó M, Ramis I, Bulbena O, Roselló J, Guarner F, Gelpi E, Balanzó J. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992;102:303-309 [PMID: 1727763]
14. Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32:157-170 [PMID: 10728802 DOI: 10.1016/S0168-8278 (00) 80423-7]
15. Knepper MA, Wade JB, Terris J, Ecelbarger CA, Marples D, Mandon B, Chou CL, Kishore BK, Nielsen S. Renal aquaporins. Kidney Int 1996;49:1712-1717 [PMID: 8743483 DOI: 10.1038/ki.1996.253]
16. Nielsen S, Marples D, Frøkiaer J, Knepper M, Agre P. The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Kidney Int 1996;49:1718-1723 [PMID: 8743484 DOI: 10.1038/ki.1996.254]
17. King LS, Agre P. Pathophysiology of the aquaporin water channels. Annu Rev Physiol 1996;58:619-648 [PMID: 8815812 DOI: 10.1146/annurev. ph.58.030196.003155]
18. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997;272:F3-12 [PMID: 9039043]
19. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549-552 [PMID: 8429910 DOI: 10.1038/361549a0]
20. Agre P, Nielsen S. The aquaporin family of water channels in kidney. Nephrologie 1996;17:409-415 [PMID: 8987045]
21. Oliet SH, Bourque CW. Mechanosensitive channels transduce osmosensitivity in supraoptic neurons. Nature 1993;364:341-343 [PMID: 7687327 DOI: 10.1038/364341a0]
22. Epstein M. Derangements of renal water handling in liver disease. Gastroenterology 1985;89:1415-1425 [PMID: 3902555]
23. Arroyo V, Clària J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994;14:44-58 [PMID: 8016662 DOI: 10.1055/s-2007-1007297]
24. Ginès P, Abraham WT, Schrier RW. Vasopressin in pathophysiological states. Semin Nephrol 1994;14:384-397 [PMID: 7938953]
25. Vaamonde CA. Renal water handling in liver disease, Epstein M, ed. The Kidney in Liver Disease, 4th ed. Philadelphia: Hanley and Belfus, Inc., 1996:33-74
26. Arroyo V, Rodés J, Gutiérrez-Lizárraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-256 [PMID: 1266841 DOI: 10.1007/BF01095898]
27. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:413-417 [PMID: 7065556 DOI: 10.7326/000 3-4819-96-4-413]
28. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006;119:S47-S53 [PMID: 16843085 DOI: 10.1016/j.amjmed.2006.05.007]
29. Warner L, Skorecki K, Blendis LM, Epstein M. Atrial natriuretic factor and liver disease. Hepatology 1993;17:500-513 [PMID: 8444424]
30. Hébert RL, Jacobson HR, Breyer MD. PGE2 inhibits AVPinduced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol 1990;259:F318-F325 [PMID: 2167017]
31. Orloff J, Handler JS, Bergstrom S. Effect of prostaglandin (pge-1) on the permeability response of toad bladder to vasopressin, theophylline and adenosine 3', 5'-monophosphate. Nature 1965;205:397-398 [PMID: 14243428 DOI: 10.1038/205397a0]
32. Anderson RJ, Berl T, McDonald KD, Schrier RW. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest 1975;56:420-426 [PMID: 1150880 DOI: 10.1172/JCI108108]
33. Walker LA, Frölich JC. Dose-dependent stimulation of renal prostaglandin synthesis by deamino-8-D-arginine vasopressin in rats with hereditary diabetes insipidus. J Pharmacol Exp Ther 1981;217:87-91 [PMID: 7205662]
34. Pérez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, Rivera F, Rodés J. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984;26:72-80 [PMID: 6434791 DOI: 10.1038/ki.1984.136]
35. Solis-Herruzo JA, Gonzalez-Gamarra A, Castellano G, Muñoz-Yagüe MT. Metabolic clearance rate of arginine vasopressin in patients with cirrhosis. Hepatology 1992;16:974-979 [PMID: 1398505 DOI: 10.1002/hep. 1840160420]
36. Kim JK, Summer SN, Howard RL, Schrier RW. Vasopressin gene expression in rats with experimental cirrhosis. Hepatology 1993;17:143-147 [PMID: 8423035]
37. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-1589 [PMID: 10824078 DOI: 10.1056/NEJM200005253422107]
38. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008;48:1002-1010 [PMID: 18671303 DOI: 10.1002/hep. 22418]
39. Solà E, Watson H, Graupera I, Turón F, Barreto R, Rodríguez E, Pavesi M, Arroyo V, Guevara M, Ginès P. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol 2012;57:1199-1206 [PMID: 22824819 DOI: 10.1016/j.jhep. 2012.07.020]
40. Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, Ríos J, Torres F, Rami L, Monté-Rubio GC, Martín-Llahí M, Arroyo V, Ginès P. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009;104:1382-1389 [PMID: 19455124 DOI: 10.1038/ajg.2009.293]
41. Llach J, Ginès P, Arroyo V, Rimola A, Titó L, Badalamenti S, Jiménez W, Gaya J, Rivera F, Rodés J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487 [PMID: 3335320]
42. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128 [PMID: 3804191]
43. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-266 [PMID: 2682175]
44. Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura PJ, Cárdenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52 [PMID: 11211907]
45. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. i. clinical and pathologic characteristics. Am J Med 1965;39:184-198 [PMID: 14320684 DOI: 10.1016/0002-934 3 (65) 90041-0]
46. Arroyo V, Bosch J, Gaya-Beltrán J, Kravetz D, Estrada L, Rivera F, Rodés J. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981;94:198-201 [PMID: 7008667 DOI: 10.7326/000 3-4819-94-2-198]
47. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343 [PMID: 15719386 DOI: 10.1002/lt.20329]
48. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810 [PMID: 15382176 DOI: 10.1002/hep. 20405]
49. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, Gassull MA, Arroyo V, Rodés J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-1501 [PMID: 7982650 DOI: 10.1002/hep. 1840200619]
50. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-1660 [PMID: 16697729 DOI: 10.1053/j.gastro.2006.02.010]
51. Londoño MC, Guevara M, Rimola A, Navasa M, Taurà P, Mas A, García-Valdecasas JC, Arroyo V, Ginès P. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-1143 [PMID: 16618408 DOI: 10.1053/j.gastro.2006.02.017]
52. Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007;13:1115-1124 [PMID: 17663412 DOI: 10.1002/lt.21154]
53. Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986;81:1033-1040 [PMID: 3799631 DOI: 10.1016/0002-9343 (86) 90401-8]
54. McCormick PA, Mistry P, Kaye G, Burroughs AK, McIntyre N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 1990;31:204-207 [PMID: 2311979 DOI: 10.1136/gut.31.2.204]
55. Bosch-Marcé M, Jiménez W, Angeli P, Leivas A, Clària J, Graziotto A, Arroyo V, Rivera F, Rodés J. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995;109:217-223 [PMID: 7797019 DOI: 10.1016/0016-5085 (95) 90287-2]
56. Moreau R, Cailmail S, Hamon G, Lebrec D. Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51, 599), in rats with cirrhosis. J Gastroenterol Hepatol 1996;11:857-863 [PMID: 8889966 DOI: 10.1111/j.1440-1746.1996.tb00093.x]
57. Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, Lebrec D. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000;32:38-42 [PMID: 10673065 DOI: 10.1016/S0168-8278 (00) 80187-7]
58. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, Chau T, Okada K, Yamamura Y, Tanaka T. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998;63:561-570 [PMID: 9630829 DOI: 10.1016/S0009-9236 (98) 90107-2]
59. Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939 [PMID: 12671890 DOI: 10.1053/gast.2003.50143]
60. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-191 [PMID: 12500203 DOI: 10.1053/jhep. 2003.50021]
61. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112 [PMID: 17105757 DOI: 10.1056/NEJMoa065181]
62. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V (2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48:204-213 [PMID: 18508290 DOI: 10.1002/hep. 22293]
63. Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, Steare S, Korula J. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther 2006;24:973-982 [PMID: 16948809 DOI: 10.1111/j.1365-2036.2006.03088.x]
64. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712 [PMID: 20185637 DOI: 10.1681/ASN.2009080857]
65. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69:2124-2130 [PMID: 16672911 DOI: 10.1038/sj.ki.5000432]
66. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011;6:2499-2507 [PMID: 21903984 DOI: 10.2215/CJN.03530411]
67. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-2418 [PMID: 23121377 DOI: 10.1056/NEJMoa1205511]
68. Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012;61:108-116 [PMID: 21836029 DOI: 10.1136/gutjnl-2011-300157]
69. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513-2515 [PMID: 6770106]
70. Solà E, Lens S, Guevara M, Martín-Llahí M, Fagundes C, Pereira G, Pavesi M, Fernández J, González-Abraldes J, Escorsell A, Mas A, Bosch J, Arroyo V, Ginès P. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology 2010;52:1783-1790 [PMID: 20931555 DOI: 10.1002/hep. 23893]